The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression

References

• Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005 Feb 4;96(2):261–268. doi: 10.1161/01.RES.0000154262.07264.12
   PubMed Web of Science ®Google Scholar
• LeClair RJ, Durmus T, Wang Q, et al. Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res. 2007 Mar 30;100(6):826–833. doi: 10.1161/01.RES.0000260806.99307.72
   PubMed Web of Science ®Google Scholar
• Mei D, Zhu Y, Zhang L, et al. The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis. Mediators Inflamm. 2020;2020:9578701.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Le Joncour V, Nummela P, et al. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget. 2016 Mar 22;7(12):15065–15092. doi: 10.18632/oncotarget.7604
   PubMedGoogle Scholar
• Stohn JP, Perreault NG, Wang Q, et al. Cthrc1, a novel circulating hormone regulating metabolism. PLOS ONE. 2012;7(10):e47142. doi: 10.1371/journal.pone.0047142
   PubMed Web of Science ®Google Scholar
• Duarte CW, Stohn JP, Wang Q, et al. Elevated plasma levels of the pituitary hormone Cthrc1 in individuals with red hair but not in patients with solid tumors. PLOS ONE. 2014;9(6):e100449. doi: 10.1371/journal.pone.0100449
   PubMed Web of Science ®Google Scholar
• Zhang R, Lu H, Lyu YY, et al. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. Sci Rep. 2017 Mar 17;7(1):44744. doi: 10.1038/srep44744
   PubMedGoogle Scholar
• He W, Zhang H, Wang Y, et al. CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9. BMC Cancer. 2018 Apr 10;18(1):400. doi: 10.1186/s12885-018-4317-6
   PubMedGoogle Scholar
• Li LY, Yin KM, Bai YH, et al. CTHRC1 promotes M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-akt signaling pathway. Clin Exp Metastasis. 2019 Aug;36:(4):351–363.
   PubMed Web of Science ®Google Scholar
• Lee J, Song J, Kwon ES, et al. CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors. Exp Mol Med. 2016 Sep 30;48(9):e261. doi: 10.1038/emm.2016.87
   PubMedGoogle Scholar
• Jiang N, Cui Y, Liu J, et al. Multidimensional roles of collagen triple helix repeat containing 1 (CTHRC1) in malignant cancers. J Cancer. 2016;7(15):2213–2220. doi: 10.7150/jca.16539
   PubMed Web of Science ®Google Scholar
• Liu YJ, Du J, Li J, et al. CTHRC1, a novel gene with multiple functions in physiology, disease and solid tumors (review). Oncol Lett. 2023 Jun;25:(6):266.
   PubMed Web of Science ®Google Scholar
• Yin H, Zhang C, Gou X, et al. Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer. Oncol Rep. 2020 Feb;43:(2):379–394.
   PubMed Web of Science ®Google Scholar
• Li Y, Cheng X, Yan J, et al. CTHRC1 facilitates bladder cancer cell proliferation and invasion through regulating the PI3K/Akt signaling pathway. Arch Med Sci. 2022;18(1):183–194. doi: 10.5114/aoms.2019.85718
   PubMed Web of Science ®Google Scholar
• Malvia S, Chintamani C, Sarin R, et al. ABERRANT EXPRESSION of COL14A1, CELRS3, and CTHRC1 in BREAST CANCER capital ES, CyrillicELLS. Exp Oncol. 2023 Jun 26;45(1):28–43. doi: 10.15407/exp-oncology.2023.01.028
   PubMedGoogle Scholar
• Wang Z, Zhang S, Zheng C, et al. CTHRC1 is a potential prognostic biomarker and correlated with macrophage infiltration in breast cancer. Int J Gen Med. 2022;15:5701–5713. doi: 10.2147/IJGM.S366272
   PubMed Web of Science ®Google Scholar
• Li H, Liu W, Zhang X, et al. Cancer-associated fibroblast-secreted collagen triple helix repeat containing-1 promotes breast cancer cell migration, invasiveness and epithelial-mesenchymal transition by activating the Wnt/beta-catenin pathway. Oncol Lett. 2021 Dec;22(6):814.
   PubMed Web of Science ®Google Scholar
• Lai YH, Chen J, Wang XP, et al. Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer. J Exp Clin Cancer Res. 2017 Jul 12;36(1):92. doi: 10.1186/s13046-017-0564-7
   PubMedGoogle Scholar
• Kim JH, Baek TH, Yim HS, et al. Collagen triple helix repeat containing-1 (CTHRC1) expression in invasive ductal carcinoma of the breast: the impact on prognosis and correlation to clinicopathologic features. Pathol Oncol Res. 2013 Oct;19:(4):731–737.
   PubMed Web of Science ®Google Scholar
• Yuan RX, Bao D, Zhang Y. Linc00707 promotes cell proliferation, invasion, and migration via the miR-30c/CTHRC1 regulatory loop in breast cancer. Eur Rev Med Pharmacol Sci. 2020 May;24(9):4863–4872. doi: 10.26355/eurrev_202005_21175
   PubMed Web of Science ®Google Scholar
• Kharaishvili G, Cizkova M, Bouchalova K, et al. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol. 2011 Nov;64:(11):977–982.
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhou Q, Liu X, et al. CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway. Oncol Rep. 2019 Mar;41:(3):1531–1538.
   PubMed Web of Science ®Google Scholar
• Cui XX, Ding HM, Gu F, et al. Inhibition of CTHRC-1 by its specific monoclonal antibody attenuates cervical cancer cell metastasis. Biomed Pharmacother. 2019 Feb;110:758–763. doi: 10.1016/j.biopha.2018.12.017
   PubMed Web of Science ®Google Scholar
• Li N, Chen L, Liu C, et al. Elevated CTHRC1 expression is an indicator for poor prognosis and lymph node metastasis in cervical squamous cell carcinoma. Hum Pathol. 2019 Mar;85:235–241. doi: 10.1016/j.humpath.2018.10.015
   PubMed Web of Science ®Google Scholar
• Xu G, Fan W, Wang F, et al. CTHRC1 as a novel biomarker in the diagnosis of cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2018;11(2):847–854.
   PubMed Web of Science ®Google Scholar
• Wang J, Akter R, Shahriar MF, et al. Cancer-associated stromal fibroblast-derived transcriptomes predict poor clinical outcomes and immunosuppression in colon cancer. Pathol Oncol Res. 2022;28:1610350. doi: 10.3389/pore.2022.1610350
   PubMed Web of Science ®Google Scholar
• Hu S, Qin J, Gao R, et al. Integrated analysis of single cell and bulk RNA sequencing identifies CTHRC1 + INHBA + CAF as drivers of colorectal cancer progression. Molecular Carcinogenesis. 2023 Aug 4;62(12):1787–1802. doi: 10.1002/mc.23615
   PubMed Web of Science ®Google Scholar
• Meng C, Zhang Y, Jiang D, et al. CTHRC1 is a prognosis-related biomarker correlated with immune infiltrates in colon adenocarcinoma. World J Surg Oncol. 2022 Mar 20;20(1):89. doi: 10.1186/s12957-022-02557-7
   PubMed Web of Science ®Google Scholar
• Pang C, Wang H, Shen C, et al. Application potential of CTHRC1 as a diagnostic and prognostic indicator for colon adenocarcinoma. Front Mol Biosci. 2022;9:849771. doi: 10.3389/fmolb.2022.849771
   PubMed Web of Science ®Google Scholar
• Ma H, Yang W, Wang X, et al. PRR11 promotes proliferation and migration of colorectal cancer through activating the EGFR/ERK/AKT pathway via increasing CTHRC1. Ann Clin Lab Sci. 2022 Jan;52(1):86–94.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Hu LP, Yang Q, et al. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer. Oncogene. 2021 Jun;40:(23):3959–3973.
   PubMed Web of Science ®Google Scholar
• Jiang F, Chen Y, Ren S, et al. Cyclovirobuxine D inhibits colorectal cancer tumorigenesis via the CTHRC1AKT/ERKSnail signaling pathway. Int J Oncol. 2020 Jul;57:(1):183–196.
   PubMed Web of Science ®Google Scholar
• Ding D, Han S, Zhang H, et al. Predictive biomarkers of colorectal cancer. Comput Biol Chem. 2019 Dec;83:107106. doi: 10.1016/j.compbiolchem.2019.107106
   PubMed Web of Science ®Google Scholar
• Ni S, Ren F, Xu M, et al. CTHRC1 overexpression predicts poor survival and enhances epithelial-mesenchymal transition in colorectal cancer. Cancer Med. 2018 Nov;7:(11):5643–5654.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Z, Xiang J, et al. MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro. Oncol Lett. 2018 Apr;15:(4):5561–5568.
   PubMed Web of Science ®Google Scholar
• Qi L, Zhang W, Cheng Z, et al. Study on molecular mechanism of ANOS1 promoting development of colorectal cancer. PLoS One. 2017;12(8):e0182964. doi: 10.1371/journal.pone.0182964
   PubMed Web of Science ®Google Scholar
• Yang XM, You HY, Li Q, et al. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling. Int J Clin Exp Pathol. 2015;8(10):12793–12801.
   PubMed Web of Science ®Google Scholar
• Yan L, Yu J, Tan F, et al. SP1-mediated microRNA-520d-5p suppresses tumor growth and metastasis in colorectal cancer by targeting CTHRC1. Am J Cancer Res. 2015;5(4):1447–1459.
   PubMed Web of Science ®Google Scholar
• Yan L, Ye GT, Shen Z, et al. Role of CTHRC1 in proliferation, migration and invasion of human colorectal cancer cells. Nan Fang Yi Ke Da Xue Xue Bao. 2015 May;35(5):767–71, 776.
   PubMedGoogle Scholar
• Kim HC, Kim YS, Oh HW, et al. Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014 Jan 30;5(2):519–529. doi: 10.18632/oncotarget.1714
   PubMedGoogle Scholar
• Tan F, Liu F, Liu H, et al. CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis. Med Oncol. 2013 Mar;30:(1):473.
   PubMed Web of Science ®Google Scholar
• Palma M, Lopez L, García M, et al. Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clin Pathol. 2012 Feb 9;12(1):2. doi: 10.1186/1472-6890-12-2
   PubMedGoogle Scholar
• Liu Y, Chen X, Xu Y, et al. CTHRC1 promotes colorectal cancer progression by recruiting tumor-associated macrophages via up-regulation of CCL15. J Mol Med (Berl). 2024 Jan;102:(1):81–94.
   PubMed Web of Science ®Google Scholar
• Hu X, Bian Y, Wen X, et al. Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway. Exp Ther Med. 2020 Aug;20:(2):1405–1414.
   PubMed Web of Science ®Google Scholar
• Bai Y, Yin K, Su T, et al. CTHRC1 in ovarian cancer promotes M2-like polarization of tumor-associated macrophages via regulation of the STAT6 signaling pathway. Onco Targets Ther. 2020;13:5743–5753. doi: 10.2147/OTT.S250520
   PubMed Web of Science ®Google Scholar
• Hou M, Cheng Z, Shen H, et al. High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. Oncotarget. 2015 Nov 3;6(34):35813–35829. doi: 10.18632/oncotarget.5358
   PubMedGoogle Scholar
• Guo B, Yan H, Li L, et al. Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer. J Ovarian Res. 2017 Oct 11;10(1):69. doi: 10.1186/s13048-017-0358-8
   PubMedGoogle Scholar
• Yang C, Liu T, Xia B, et al. Correlation of collagen triple helix repeat containing 1 overexpression with lymph node and peritoneal metastasis in epithelial ovarian cancer. Int J Gynecol Cancer. 2017 Jan;27:(1):22–27.
   PubMed Web of Science ®Google Scholar
• Ye J, Chen W, Wu ZY, et al. Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling. Oncol Rep. 2016 Dec;36:(6):3588–3596.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou J, Wang J, et al. Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene. Biol Res. 2020 Mar 10;53(1):10. doi: 10.1186/s40659-020-00277-4
   PubMed Web of Science ®Google Scholar
• Kokabi F, Khosravi A, Jazi MS, et al. A reliable mouse model of liver and lung metastasis by injecting esophageal cancer stem cells (CSCs) through tail-vein injection. Mol Biol Rep. 2023 Apr;50:(4):3401–3411.
   PubMed Web of Science ®Google Scholar
• Orloff M, Peterson C, He X, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011 Jul 27;306(4):410–419. doi: 10.1001/jama.2011.1029
   PubMed Web of Science ®Google Scholar
• Deng H, Lin Y, Gan F, et al. Prognostic model and immune infiltration of ferroptosis subcluster-related modular genes in gastric cancer. J Oncol. 2022;2022:5813522. doi: 10.1155/2022/5813522
   PubMed Web of Science ®Google Scholar
• Hu Y, Huang L, Zhao K, et al. CTHRC1 is associated with immune escape and poor prognosis in gastric cancer. Anticancer Res. 2023 Jan;43:(1):115–126.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yue B, Duan X, et al. Joint analysis identified FAP as a prognostic and diagnostic biomarker correlated immune infiltration in gastric cancer. Pathol Res Pract. 2023 May;245:154462. doi: 10.1016/j.prp.2023.154462
   PubMed Web of Science ®Google Scholar
• Sun C, Chen Y, Kim NH, et al. Identification and verification of potential biomarkers in gastric cancer by integrated bioinformatic analysis. Front Genet. 2022;13:911740. doi: 10.3389/fgene.2022.911740
   PubMed Web of Science ®Google Scholar
• Chivu-Economescu M, Necula LG, Matei L, et al. Collagen family and other matrix remodeling proteins identified by bioinformatics analysis as hub genes involved in gastric cancer progression and prognosis. Int J Mol Sci. 2022 Mar 16;23(6):3214. doi: 10.3390/ijms23063214
   PubMed Web of Science ®Google Scholar
• Zhu Z, Xu J, Li L, et al. Comprehensive analysis reveals CTHRC1, SERPINE1, VCAN and UPK1B as the novel prognostic markers in gastric cancer. Transl Cancer Res TCR. 2020 Jul;9:(7):4093–4110.
   PubMed Web of Science ®Google Scholar
• Ding X, Huang R, Zhong Y, et al. CTHRC1 promotes gastric cancer metastasis via HIF-1alpha/CXCR4 signaling pathway. Biomed Pharmacother. 2020 Mar;123:109742. doi: 10.1016/j.biopha.2019.109742
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu S, Zhan H, et al. Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma. Mol Med Rep. 2018 Oct;18:(4):3673–3682.
   PubMed Web of Science ®Google Scholar
• Song Z, Liu W, Xiao Y, et al. PRR11 is a prognostic marker and potential oncogene in patients with gastric cancer. PLOS ONE. 2015;10(8):e0128943. doi: 10.1371/journal.pone.0128943
   PubMed Web of Science ®Google Scholar
• Yu J, Feng J, Zhi X, et al. Let-7b inhibits cell proliferation, migration, and invasion through targeting Cthrc1 in gastric cancer. Tumour Biol. 2015 May;36:(5):3221–3229.
   PubMedGoogle Scholar
• Gu L, Liu L, Zhong L, et al. Cthrc1 overexpression is an independent prognostic marker in gastric cancer. Hum Pathol. 2014 May;45:(5):1031–1038.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang YC, Chen XY, et al. CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer. Cancer Sci. 2012 Jul;103:(7):1327–1333.
   PubMed Web of Science ®Google Scholar
• Ma MZ, Zhuang C, Yang XM, et al. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia. 2014 Mar;16:(3):265–78, 278 e1–13.
   Web of Science ®Google Scholar
• Liu J, Li W, Liu S, et al. Knockdown of collagen triple helix repeat containing 1 (CTHRC1) inhibits epithelial-mesenchymal transition and cellular migration in glioblastoma cells. Oncol Res. 2017 Jan 26;25(2):225–232. doi: 10.3727/096504016X14732772150587
   PubMed Web of Science ®Google Scholar
• Wei C, Zhang X, Peng D, et al. LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway. Cell Death Dis. 2022 Nov 9;13(11):942. doi: 10.1038/s41419-022-05393-5
   PubMed Web of Science ®Google Scholar
• Mei PJ, Bai J, Miao FA, et al. CTHRC1 mediates multiple pathways regulating cell invasion, migration and adhesion in glioma. Int J Clin Exp Pathol. 2017;10(9):9318–9329.
   PubMed Web of Science ®Google Scholar
• Song L, Li Q, Lu Y, et al. Cancer progression mediated by CAFs relating to HCC and identification of genetic characteristics influencing prognosis. J Oncol. 2022;2022:1–16. doi: 10.1155/2022/2495361
   Web of Science ®Google Scholar
• Zhou H, Su L, Liu C, et al. CTHRC1 may serve as a prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther. 2019;12:7823–7831. doi: 10.2147/OTT.S219429
   PubMed Web of Science ®Google Scholar
• Wang Y, Lee M, Yu G, et al. CTHRC1 activates pro-tumorigenic signaling pathways in hepatocellular carcinoma. Oncotarget. 2017 Dec 1;8(62):105238–105250. doi: 10.18632/oncotarget.22164
   PubMedGoogle Scholar
• Chen G, Wang D, Zhao X, et al. miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3beta-involved Wnt/beta-catenin signaling. Cancer Cell Int. 2017;17:118. doi: 10.1186/s12935-017-0469-8
   PubMed Web of Science ®Google Scholar
• Wang CY, Zhang JJ, Hua L, et al. MicroRNA-98 suppresses cell proliferation, migration and invasion by targeting collagen triple helix repeat containing 1 in hepatocellular carcinoma. Mol Med Rep. 2016 Mar;13:(3):2639–2644.
   PubMed Web of Science ®Google Scholar
• Zhang R, Cao Y, Bai L, et al. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades. Mol Carcinog. 2015 Dec;54:(12):1554–1566.
   PubMed Web of Science ®Google Scholar
• Tameda M, Sugimoto K, Shiraki K, et al. Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility. Int J Oncol. 2014 Aug;45:(2):541–548.
   PubMed Web of Science ®Google Scholar
• Chen YL, Wang TH, Hsu HC, et al. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One. 2013;8(7):e70324. doi: 10.1371/journal.pone.0070324
   PubMed Web of Science ®Google Scholar
• Yang J, Liu K, Yang L, et al. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing. Front Immunol. 2023;14:1174762. doi: 10.3389/fimmu.2023.1174762
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu T, Li X, et al. Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis. J Clin Lab Anal. 2022 May;36:(5):e24412.
   PubMed Web of Science ®Google Scholar
• Yang C, Huang T, Liang Y, et al. CTHRC1 targeted by miR-30a-5p regulates cell adhesion, invasion and migration in lung adenocarcinoma. J Cardiothorac Surg. 2022 Mar 21;17(1):46. doi: 10.1186/s13019-022-01788-9
   PubMed Web of Science ®Google Scholar
• Shen R, Cai X, Shen D, et al. Long noncoding RNA LINC00518 contributes to proliferation and metastasis in lung adenocarcinoma via the miR-335-3p/CTHRC1 axis. Cell Death Discov. 2022 Mar 4;8(1):98. doi: 10.1038/s41420-022-00905-w
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun Y, Cui Y, et al. High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients. Cancer Cell Int. 2019;19(1):318. doi: 10.1186/s12935-019-1041-5
   PubMed Web of Science ®Google Scholar
• Chen S, Li P, Yang R, et al. microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer. Cancer Cell Int. 2015;15(1):85. doi: 10.1186/s12935-015-0236-7
   PubMedGoogle Scholar
• Ke Z, He W, Lai Y, et al. Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. Oncotarget. 2014 Oct 15;5(19):9410–9424. doi: 10.18632/oncotarget.2421
   PubMedGoogle Scholar
• Liu X, Liu B, Cui Y, et al. Collagen triple helix repeat containing 1 (Cthrc1) is an independently prognostic biomarker of non-small cell lung cancers with cigarette smoke. Tumour Biol. 2014 Nov;35:(11):11677–11683.
   PubMedGoogle Scholar
• Tang L, Dai DL, Su M, et al. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006 Jun 15;12(12):3716–3722. doi: 10.1158/1078-0432.CCR-06-0030
   PubMed Web of Science ®Google Scholar
• Ip W, Wellman-Labadie O, Tang L, et al. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. J Cutan Med Surg. 2011 Mar;15:(2):103–110.
   PubMed Web of Science ®Google Scholar
• Yuan K, Sun Y, Ji Y. miR-509-3p suppresses migration, invasion, and epithelial- mesenchymal transition in melanoma cells by targeting collagen triple helix repeat containing 1. Balkan Med J. 2021 May;38(3):177–182. doi: 10.5152/balkanmedj.2021.20049
   PubMed Web of Science ®Google Scholar
• Li Y, Fu Y, Gao Y, et al. microRNA-134 inhibits melanoma growth and metastasis by negatively regulating collagen triple helix repeat containing-1 (CTHRC1). Int J Clin Exp Pathol. 2018;11(9):4319–4330.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Ma C, et al. Overexpression of CTHRC1 in human melanoma promotes tumorigenesis targeted by miRNA155. Int J Clin Exp Pathol. 2017;10(8):8199–8210.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Le Joncour V, Jahkola T, et al. Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls. Mol Oncol. 2020 Apr;14:(4):742–762.
   PubMed Web of Science ®Google Scholar
• Johanson KO, Haynes TE, McHenry CS. Chemical characterization and purification of the beta subunit of the DNA polymerase III holoenzyme from an overproducing strain. J Biol Chem. 1986 Sep 5;261(25):11460–11465. doi: 10.1016/S0021-9258(18)67266-7
   PubMed Web of Science ®Google Scholar
• Lee CE, Vincent-Chong VK, Ramanathan A, et al. Collagen triple helix repeat containing-1 (CTHRC1) expression in oral squamous cell carcinoma (OSCC): prognostic value and clinico-pathological implications. Int J Med Sci. 2015;12(12):937–945. doi: 10.7150/ijms.11605
   PubMed Web of Science ®Google Scholar
• Liu G, Sengupta PK, Jamal B, et al. N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration. J Biol Chem. 2013 Jul 12;288(28):20217–20227. doi: 10.1074/jbc.M113.473785
   PubMed Web of Science ®Google Scholar
• Liu Y, Abulimiti N, Wang C. Collagen triple helix repeat containing 1 expression in osteosarcoma: a new predictor of prognosis. Ann Clin Lab Sci. 2018 May;48(3):338–344.
   PubMed Web of Science ®Google Scholar
• Sang W, Zhu L, Ma J, et al. Lentivirus-mediated knockdown of CTHRC1 inhibits osteosarcoma cell proliferation and migration. Cancer Biother Radiopharm. 2016 Apr;31:(3):91–98.
   PubMed Web of Science ®Google Scholar
• Kang MK, Jiang F, Kim YJ, et al. CTHRC1 induces pancreatic stellate cells (PSCs) into myofibroblast-like cancer-associated fibroblasts (myCafs). Cancers (Basel). 2023 Jun 27;15(13):3370. doi: 10.3390/cancers15133370
   PubMed Web of Science ®Google Scholar
• Xu H, Hua J, Meng Q, et al. Hyperdense pancreatic ductal adenocarcinoma: clinical characteristics and proteomic landscape. Front Oncol. 2021;11:640820. doi: 10.3389/fonc.2021.640820
   PubMed Web of Science ®Google Scholar
• Liu W, Fu XL, Yang JY, et al. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Am J Cancer Res. 2016;6(8):1820–1827.
   PubMed Web of Science ®Google Scholar
• Park EH, Kim S, Jo JY, et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis. 2013 Mar;34:(3):694–702.
   PubMed Web of Science ®Google Scholar
• Chen Y, Jia L, Zhao K, et al. CTHRC1 promotes anaplastic thyroid cancer progression by upregulating the proliferation, migration, and invasion of tumor cells. PeerJ. 2023;11:e15458. doi: 10.7717/peerj.15458
   PubMed Web of Science ®Google Scholar
• Tang Z, Ding X, Qin S, et al. Effects of RNA interference of CTHRC1 on proliferation and apoptosis of thyroid papillary cancer TCP-1 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 2021 Apr 20;41(4):549–554. doi: 10.12122/j.issn.1673-4254.2021.04.10
   PubMedGoogle Scholar
• Tang ZN, Wang YC, Liu XX, et al. An immunohistochemical study of CTHRC1,Vimentin,E-cadherin expression in papillary thyroid carcinoma. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Apr;32:(8):595–598.
   PubMedGoogle Scholar
• Wong HY, Sheng Q, Hesterberg AB, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022 Oct 13;13(1):6036. doi: 10.1038/s41467-022-33780-1
   PubMed Web of Science ®Google Scholar
• Ma Z, Chao F, Wang S, et al. CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. Biochem Biophys Res Commun. 2020 Apr 30;525(2):418–424. doi: 10.1016/j.bbrc.2020.02.098
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xiong W, Zhou X, et al. CTHRC1 and PD1/PDL1 expression predicts tumor recurrence in prostate cancer. Mol Med Rep. 2019 Nov;20:(5):4244–4252.
   PubMed Web of Science ®Google Scholar
• Bacolod MD, Barany F. A unified transcriptional, pharmacogenomic, and gene dependency approach to decipher the biology, diagnostic markers, and therapeutic targets associated with prostate cancer metastasis. Cancers (Basel). 2021 Oct 14;13(20):5158. doi: 10.3390/cancers13205158
   PubMed Web of Science ®Google Scholar
• Wang L, Xiang YN, Zhang YH, et al. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma. Br J Dermatol. 2011 Jan;164:(1):135–140.
   PubMed Web of Science ®Google Scholar
• Qi C, Hu Y, Yang F, et al. Preliminary observations regarding the expression of collagen triple helix repeat-containing 1 is an independent prognostic factor for Wilms’ tumor. J Pediatr Surg. 2016 Sep;51:(9):1501–1506.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Z, Shao F, et al. High expression of collagen triple helix repeat containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. J Exp Clin Cancer Res. 2017 Jun 23;36(1):84. doi: 10.1186/s13046-017-0555-8
   PubMedGoogle Scholar
• Yin WH, Fan HZ, Sheng JW, et al. Effect of vascular endothelial growth factor C and collagen triple helix repeat containing 1 expression on prognosis of rectal carcinoma patients. Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jul;16(7):673–675.
   PubMedGoogle Scholar
• Jin XF, Li H, Zong S, et al. Knockdown of collagen triple helix repeat containing-1 inhibits the proliferation and epithelial-to-mesenchymal transition in renal cell carcinoma cells. Oncol Res. 2016 Oct 27;24(6):477–485. doi: 10.3727/096504016X14685034103716
   PubMed Web of Science ®Google Scholar
• Han S, Zhu W, Yang W, et al. A prognostic signature constructed by CTHRC1 and LRFN4 in stomach adenocarcinoma. Front Genet. 2021;12:646818. doi: 10.3389/fgene.2021.646818
   PubMedGoogle Scholar
• Saling M, Duckett JK, Ackers I, et al. Wnt5a/Planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker. Oncotarget. 2017 May 9;8(19):31655–31665. doi: 10.18632/oncotarget.15877
   PubMedGoogle Scholar
• Zhong R, Yang M, Zhu R, et al. CTHRC1 is associated with immune cell infiltration and functions as an adverse marker for prognosis in head and neck squamous cell carcinoma. Oncol Lett. 2023 Apr;25:(4):133.
   PubMed Web of Science ®Google Scholar
• Harikrishnan K, Prabhu SS, Balasubramanian N. A pan-cancer analysis of matrisome proteins reveals CTHRC1 and a related network as major ECM regulators across cancers. PLoS One. 2022;17(10):e0270063.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wang W, Niu P, et al. The molecular mechanisms of CTHRC1 in gastric cancer by integrating TCGA, GEO and GSA datasets. Front Genet. 2022;13:900124. doi: 10.3389/fgene.2022.900124
   PubMed Web of Science ®Google Scholar
• Peng D, Wei C, Zhang X, et al. Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. Cancer Cell Int. 2021 Oct 26;21(1):566. doi: 10.1186/s12935-021-02266-3
   PubMed Web of Science ®Google Scholar
• Sial N, Ahmad M, Hussain MS, et al. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci Rep. 2021 Oct 6;11(1):19873. doi: 10.1038/s41598-021-99321-w
   PubMed Web of Science ®Google Scholar
• Kramer A, Green J, Pollard J Jr., et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014 Feb 15;30(4):523–530. doi: 10.1093/bioinformatics/btt703
   PubMed Web of Science ®Google Scholar
• Tang SC, Chen YC. Novel therapeutic targets for pancreatic cancer. World J Gastroenterol. 2014 Aug 21;20(31):10825–10844. doi: 10.3748/wjg.v20.i31.10825
   PubMed Web of Science ®Google Scholar
• Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005 Dec;14(6):1583–1588. doi: 10.3892/or.14.6.1583
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nishimura O, Misaki K, et al. Cthrc1 selectively activates the planar cell polarity pathway of wnt signaling by stabilizing the wnt-receptor complex. Dev Cell. 2008 Jul;15:(1):23–36.
   PubMed Web of Science ®Google Scholar
• Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016 Feb 24;15(1):18. doi: 10.1186/s12943-016-0502-x
   PubMedGoogle Scholar
• Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18:(3):175–196.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807–821. doi: 10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020 Mar;70(2):86–104. doi: 10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Thornton J, Chhabra G, Singh CK, et al. Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter. Front Oncol. 2022;12:880876. doi: 10.3389/fonc.2022.880876
   PubMed Web of Science ®Google Scholar
• Gupta R. Epigenetic regulation and targeting of ECM for cancer therapy. Am J Physiol Cell Physiol. 2022 Apr 1;322(4):C762–C768. doi: 10.1152/ajpcell.00022.2022
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen Z, Fang Y, et al. Prediction of prognosis and recurrence of bladder cancer by ECM-Related genes. J Immunol Res. 2022;2022:1–16. doi: 10.1155/2022/1793005
   Web of Science ®Google Scholar
• Zhou F, Shen D, Xiong Y, et al. CTHRC1 is a Prognostic Biomarker and correlated with immune infiltrates in kidney renal papillary cell carcinoma and kidney renal clear cell carcinoma. Front Oncol. 2020;10:570819. doi: 10.3389/fonc.2020.570819
   PubMed Web of Science ®Google Scholar
• Yang J, Hong S, Zhang X, et al. Tumor immune microenvironment related gene-based model to predict prognosis and response to compounds in ovarian cancer. Front Oncol. 2021;11:807410. doi: 10.3389/fonc.2021.807410
   PubMed Web of Science ®Google Scholar
• Han SJ, Lee JE, Cho YJ, et al. Genomic function of estrogen receptor beta in endometriosis. Endocrinology. 2019 Nov 1;160(11):2495–2516. doi: 10.1210/en.2019-00442
   PubMed Web of Science ®Google Scholar
• Canes L, Marti-Pamies I, Ballester-Servera C, et al. High NOR-1 (neuron-derived orphan receptor 1) expression strengthens the vascular wall response to angiotensin II leading to aneurysm formation in mice. Hypertension. 2021 Feb;77:(2):557–570.
   PubMed Web of Science ®Google Scholar
• Hironaka T, Takizawa N, Yamauchi Y, et al. The well-developed actin cytoskeleton and Cthrc1 expression by actin-binding protein drebrin in myofibroblasts promote cardiac and hepatic fibrosis. J Biol Chem. 2023 Mar;299:(3):102934.
   PubMed Web of Science ®Google Scholar
• van Berlo JH, Elrod JW, Aronow BJ, et al. Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12331–12336. doi: 10.1073/pnas.1104499108
   PubMed Web of Science ®Google Scholar
• Dong W, Zhao Y, Wen D, et al. Wnt4 is crucial for cardiac repair by regulating mesenchymal-endothelial transition via the phospho-JNK/JNK. Theranostics. 2022;12(9):4110–4126. doi: 10.7150/thno.71392
   PubMed Web of Science ®Google Scholar
• Hsu A, Duan Q, Day DS, et al. Targeting transcription in heart failure via CDK7/12/13 inhibition. Nat Commun. 2022 Jul 27;13(1):4345. doi: 10.1038/s41467-022-31541-8
   PubMed Web of Science ®Google Scholar
• Spector I, Zilberstein Y, Lavy A, et al. The involvement of collagen triple helix repeat containing 1 in muscular dystrophies. Am J Pathol. 2013 Mar;182:(3):905–916.
   PubMed Web of Science ®Google Scholar
• Matus DQ, Lohmer LL, Kelley LC, et al. Invasive cell fate requires G1 cell-cycle arrest and histone deacetylase-mediated changes in gene expression. Dev Cell. 2015 Oct 26;35(2):162–174. doi: 10.1016/j.devcel.2015.10.002
   PubMed Web of Science ®Google Scholar
• Li J, Cao J, Li M, et al. Collagen triple helix repeat containing-1 inhibits transforming growth factor-b1-induced collagen type I expression in keloid. Br J Dermatol. 2011 May;164:(5):1030–1036.
   PubMed Web of Science ®Google Scholar
• Myngbay A, Manarbek L, Ludbrook S, et al. The role of collagen triple helix repeat-containing 1 protein (CTHRC1) in rheumatoid arthritis. Int J Mol Sci. 2021 Feb 28;22(5):2426. doi: 10.3390/ijms22052426
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Q, Sun H. Role of collagen triple helix repeat containing-1 in tumor and inflammatory diseases. J Cancer Res Ther. 2017;13(4):621–624. doi: 10.4103/jcrt.JCRT_410_17
   PubMed Web of Science ®Google Scholar